How do emerging markets support EPD growth?

Emerging markets support EPD growth through strong demand for affordable branded generics, biosimilar expansion, and new regulatory approvals.

What are biosimilars?

Biosimilars are biologic products that mimic original biologic drugs in efficacy and safety but at a lower cost.

Emerging Markets Fuel Abbott's EPD Momentum, Says Zacks

Abbott Laboratories' Established Pharmaceuticals Division (EPD) is seeing momentum driven by emerging markets, with strong demand for branded generics, biosimilar expansion, and new approvals, according to Zacks.

June 24, 2026

2 min read

Source: Zacks

A Zacks analysis highlighted that Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) is experiencing momentum supported by emerging markets, where demand for branded generics is strong alongside biosimilar expansion and new regulatory approvals.

Key Driver Details

Abbott's strategy in emerging markets focuses on offering branded generics at competitive prices, catering to populations seeking affordable treatment options. The company is also expanding its biosimilars portfolio, which mimics original biologic drugs at lower costs.

Context

These developments come as Abbott continues to strengthen its presence in emerging markets, a key growth driver for the global pharmaceutical sector. The company has recently secured new regulatory approvals for its products in several countries, accelerating growth momentum.

What This Means for Investors

While the future performance of the EPD unit depends on multiple factors, the focus on emerging markets may provide a stable growth opportunity for Abbott, especially amid rising healthcare demand in those regions.

Frequently Asked Questions

EPD stands for Established Pharmaceuticals Division, which focuses on branded generics and biosimilars.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.